Actinogen XanaMIA Part A trial results expected in April
Filed with ASX · · 3 pages · English
Sydney, 11 February 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that following the final trial patient visit yesterday it now expects top-line results for the XanaMIA 1 Part A trial to be available in April , allowing for an approximate two-month period of data entry, quality control and analysis. • The XanaMIA Part A Phase 2 trial: o Enrolled 107 healthy volun
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen appoints XanaFX Phase 2 trial manager
- Actinogen Medical: ACW CEO Presents at San Francisco Healthcare Conference
- Capital Raising Completion
- ACW Strategic Collaboration with Oxford Uni Researchers
- XanaMIA Part A trial achieves target enrolment
Later from Actinogen Medical
- Appendix 4D & Half-Year Financial Statements
- Actinogen Medical: ACW CEO Presents at European Life Sciences Conference
- Letter to Shareholders & Notice of General Meeting
- ACW announces positive XanaMIA results for Xanamem
- ACW positive XanaMIA results webcast slide presentation
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical